Escient Pharmaceuticals Announces IND Clearance by FDA To Start Phase 1 Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist For Mast Cell Mediated Disorders Portfolio News / By Karina Tin January 30, 2023
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics Portfolio News / By Karina Tin January 10, 2023
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Portfolio News / By Karina Tin January 9, 2023
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities Portfolio News / By Karina Tin January 9, 2023
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones Portfolio News / By Karina Tin January 9, 2023
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities Portfolio News / By Karina Tin January 9, 2023
Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics Portfolio News / By Karina Tin January 6, 2023
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease Portfolio News / By Karina Tin January 5, 2023
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update Portfolio News / By Karina Tin January 5, 2023
Remix Therapeutics Appoints Christopher Bowden, M.D., as Chief Medical Officer Portfolio News / By Karina Tin January 5, 2023
